Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures (2016 - 2025)

Collegium Pharmaceutical has reported Gains from Sales and Divestitures over the past 10 years, most recently at $980992.0 for Q3 2025.

  • Quarterly results put Gains from Sales and Divestitures at $980992.0 for Q3 2025, up 90.84% from a year ago — trailing twelve months through Sep 2025 was $980992.0 (up 90.84% YoY), and the annual figure for FY2024 was $967773.0, up 333.65%.
  • Gains from Sales and Divestitures for Q3 2025 was $980992.0 at Collegium Pharmaceutical, up from $895705.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for COLL hit a ceiling of $980992.0 in Q3 2025 and a floor of $66974.0 in Q2 2021.
  • Median Gains from Sales and Divestitures over the past 5 years was $514050.0 (2024), compared with a mean of $507047.5.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 75.97% in 2021 and later soared 718.27% in 2022.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures stood at $444769.0 in 2021, then grew by 28.88% to $573204.0 in 2022, then crashed by 61.07% to $223170.0 in 2023, then skyrocketed by 333.65% to $967773.0 in 2024, then increased by 1.37% to $980992.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $980992.0 (Q3 2025), $895705.0 (Q2 2025), and $792945.0 (Q1 2025) per Business Quant data.